Autoimmune Diseases

Acella Recalls 2 Lots of Thyroid Medication for Subpotency

September 22, 2020

Two lots of the thyroid tablets are being recalled after testing found the lots to be subpotent.

Antibiotics Linked to Higher Risk of Inflammatory Bowel Disease

September 11, 2020

Higher cumulative exposure to systemic antibiotic therapy may be associated with a greater risk of new-onset inflammatory bowel disease.

Prevent Medication Errors in Autoimmune Disease

September 10, 2020

Pharmacists can play an important role in educating patients about autoimmune drugs to prevent medication errors.

Opicapone Can Help Treat Patients Experiencing “Off” Episodes With Parkinson Disease

August 21, 2020

Levodopa/carbidopa is currently the gold standard for controlling motor symptoms associated with Parkinson disease.

FDA OKs Ofatumumab for Treatment of Relapsing Multiple Sclerosis

August 20, 2020

Ofatumumab (Kesimpta; Novartis) is the first and only self-administered, targeted B-cell therapy for the treatment of relapsing multiple sclerosis.

FDA Approves Satralizumab-mwge for Treatment of Rare Autoimmune Disease

August 18, 2020

The therapy received fast track designation and was approved in just over 1 year.

Investigators Find COVID-19 Connection in Vasculitis

August 14, 2020

A Kawasaki-like inflammatory disease has affected children who have coronavirus disease 2019.

Investigational Long-Acting Injectable Cabotegravir Shows Superior Efficacy Over Daily Oral PrEP

July 13, 2020

The data from a new study has shown that investigational, long-acting injectable cabotegravir boasted a 66% higher efficacy than daily oral pills in preventing HIV-1.

Women With HIV and Persistent Depression May Experience Greater Risk for Heart Disease

July 03, 2020

A new study found increased plaque buildup levels in women with HIV who also suffered from persistent depression and stress.

Studies Reveal Positive Results for Infliximab Biosimilar

June 18, 2020

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.